Insider Intelligence delivers leading-edge research to clients in a variety of forms, including full-length reports and data visualizations to equip you with actionable takeaways for better business decisions.
In-depth analysis, benchmarks and shorter spotlights on digital trends.
Learn More
Interactive projections with 10k+ metrics on market trends, & consumer behavior.
Learn More
Proprietary data and over 3,000 third-party sources about the most important topics.
Learn More
Industry KPIs
Industry benchmarks for the most important KPIs in digital marketing, advertising, retail and ecommerce.
Learn More
Client-only email newsletters with analysis and takeaways from the daily news.
Learn More
Analyst Access Program
Exclusive time with the thought leaders who craft our research.
Learn More

About Insider Intelligence

Our goal at Insider Intelligence is to unlock digital opportunities for our clients with the world’s most trusted forecasts, analysis, and benchmarks. Spanning five core coverage areas and dozens of industries, our research on digital transformation is exhaustive.
Our Story
Learn more about our mission and how Insider Intelligence came to be.
Learn More
Rigorous proprietary data vetting strips biases and produces superior insights.
Learn More
Our People
Take a look into our corporate culture and view our open roles.
Join the Team
Contact Us
Speak to a member of our team to learn more about Insider Intelligence.
Contact Us
See our latest press releases, news articles or download our press kit.
Learn More
Advertising & Sponsorship Opportunities
Reach an engaged audience of decision-makers.
Learn More
Browse our upcoming and past events, recent podcasts, and other featured resources.
Learn More
Tune in to eMarketer's daily, weekly, and monthly podcasts.
Learn More

GoodRx’s underperformance in Q2 could be temporary as more consumers seek discounts for healthcare services

The news: GoodRx reported a net loss of $1.4 million in Q2. That’s a 105% decrease in net income compared with the $31.1 million the company earned during Q2 of last year.

How we got here: The drug discount platform attributed its year-over-year decreases partially to costs of its recent vitaCare acquisition and the loss of a big customer.

  • In February, GoodRx acquired prescription services vitaCare in a $150 million deal.
  • In May, GoodRx anticipated its Q2’22 earnings would tumble after a major grocery store chain stopped accepting its drug discounts. It didn’t specify which grocery chain pulled out.

The bigger picture: GoodRx says it resolved its issue with the grocery store customer, which means revenues could rise again this year.

This won’t be immediate, though. GoodRx doesn't expect a “meaningful volume or revenue lift” in Q3 based on the rollout timeline of communication with the grocer, new user adoption, and returning user levels.

The silver lining: Consumers are becoming more conservative with their purchases in the era of uncertainty, which could actually make drug discount platforms like GoodRx even more popular this year.

  • About 9% of US adult consumers say healthcare is the first area they’d make cutbacks due to tighter household budgets, per a June 2022 YouGov survey.
  • That means more consumers will be on the hunt for healthcare deals. About 13% of consumers say they’ve switched to a more affordable medication alternative due to rising prescription costs, per a 2021 GoodRx survey of over 1,000 US adults.